Polyphenon Pharma Report issue

For profit Phase 1 Phase 2
Founded: New York NY United States (2005)
Status: Left NME R&D (2011)

Organization Overview

First Clinical Trial
2005
NCT00676780
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

green tea (1 trial)

Drugs in Phase 1 Trials (2)

erlotinib (tarceva) (1 trial)

l-epigallocatechin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Head and Neck Neoplasms (Phase 1)

Precancerous Conditions (Phase 1)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3